|
Investment in Saneron CCEL Therapeutics, Inc. (''Saneron'') - Additional Information (Detail) (USD $)
|
3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aug. 31, 2014
|
Nov. 30, 2013
|
Aug. 31, 2014
Accumulated Deficit [Member]
|
Aug. 31, 2014
Treasury Stock [Member]
|
Aug. 31, 2014
Saneron [Member]
|
Aug. 31, 2014
Saneron [Member]
Installment
|
Nov. 30, 2013
Saneron [Member]
|
Aug. 31, 2014
Saneron [Member]
Valuation Allowance Investment [Member]
|
Aug. 31, 2014
Saneron [Member]
Valuation Allowance Investment [Member]
|
Aug. 31, 2014
Saneron [Member]
Common Stock and Warrant Awards [Member]
|
Aug. 31, 2013
Saneron [Member]
Common Stock and Warrant Awards [Member]
|
Aug. 31, 2014
Saneron [Member]
Common Stock and Warrant Awards [Member]
|
Aug. 31, 2013
Saneron [Member]
Common Stock and Warrant Awards [Member]
|
Aug. 31, 2014
Saneron [Member]
Initial Loan [Member]
Installment
|
Aug. 31, 2014
Saneron [Member]
Additional Loan [Member]
Installment
|
|
| Investments In Affiliates [Line Items] | |||||||||||||||
| Ownership interest | 33.00% | 33.00% | 34.00% | ||||||||||||
| Equity method investment | $ 758,764 | $ 684,000 | $ 758,764 | $ 758,764 | $ 684,000 | ||||||||||
| Goodwill | 684,000 | ||||||||||||||
| Equity method investment, other than temporary impairment loss | 0 | 0 | |||||||||||||
| Goodwill impairment loss | 0 | 0 | |||||||||||||
| Loan Saneron in quarterly payments an aggregate amount | 300,000 | 300,000 | |||||||||||||
| Initial loan amount | 150,000 | 150,000 | 150,000 | ||||||||||||
| Additional quarterly payments | 4 | 4 | 4 | ||||||||||||
| Quarterly installments per quarter | 37,500 | 37,500 | |||||||||||||
| Date of maturity | 5 years | ||||||||||||||
| Quarterly installments per quarter | 37,500 | ||||||||||||||
| Equity in losses | 53,000 | 242,000 | 8,500 | 39,000 | 86,000 | 115,000 | |||||||||
| Valuation allowances on investment | 37,500 | 150,000 | |||||||||||||
| Common shares repurchased | 93,800 | ||||||||||||||
| Common shares per share value | $ 2.60 | $ 2.60 | |||||||||||||
| Common shares sold by Saneron | 56,300 | ||||||||||||||
| Reclassification from treasury stock to accumulated deficit. | $ (400,000) | $ 400,000 | |||||||||||||